Show simple item record

dc.contributor.authorBarros, Elizabete Ribeiro [UNIFESP]
dc.contributor.authorSilva, Magnus R. Dias da [UNIFESP]
dc.contributor.authorKunii, Ilda S. [UNIFESP]
dc.contributor.authorLazaretti-Castro, Marise [UNIFESP]
dc.date.accessioned2018-06-15T18:07:33Z
dc.date.available2018-06-15T18:07:33Z
dc.date.issued2008-08-01
dc.identifierhttp://dx.doi.org/10.1515/JPEM.2008.21.8.811
dc.identifier.citationJournal Of Pediatric Endocrinology & Metabolism. Tel Aviv: Freund Publishing House Ltd, v. 21, n. 8, p. 811-818, 2008.
dc.identifier.issn0334-018X
dc.identifier.urihttp://repositorio.unifesp.br/11600/44543
dc.description.abstractOsteoporosis-pseudoglioma (OPPG) is a rare syndrome characterized by severe osteoporosis and ocular defects caused by homozygotic inactivation mutations in the LRP5 gene. Bisphosphonate has been demonstrated to improve bone mineral density (BMD) in children with OPPG. We present here a 3 years follow-up of two brothers with OPPG carrying a novel mutation in the LRP5 gene, who were treated with intravenous pamidronate.Patient Report: We looked for a mutation in the LRP5 gene in two brothers (12 and 4 years old) with clinical features of OPPG (blindness, low BMD and fragility fractures) and in their consanguineous parents to confirm the diagnosis of OPPG. The patients were treated with bisphosphonate for 3 years. They received 1 mg/kg/day of pamidronate for 2 consecutive days, every 3 months during the first year, and every 4 months in subsequent years. Calcium, phosphorus, total alkaline phosphatase, parathyroid hormone, hepatic transaminases, creatinine and hemogram tests were performed before each infusion. Bone densitometry was performed at baseline and at the end of the follow-up.Results and Conclusion: The affected brothers carry a missense mutation in the third codon of exon 8 (AAT -> ATT) that led to the exchange of an asparagine for an isoleucine (N531I). Both parents were found to be heterozygous for this mutation. The intravenous pamidronate therapy was safe for up to 3 years of use. Moreover, increased BMD and decreased fracture rate were observed in our patients with OPPG.en
dc.format.extent811-818
dc.language.isoeng
dc.publisherFreund Publishing House Ltd
dc.relation.ispartofJournal Of Pediatric Endocrinology & Metabolism
dc.rightsAcesso restrito
dc.subjectosteoporosis-pseudogliomaen
dc.subjectLRP5en
dc.subjectskeletal fragilityen
dc.subjectbisphosphonateen
dc.titleThree years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutationen
dc.typeArtigo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.description.affiliationUniv Fed Sao Paulo, Div Endocrinol, BR-04039032 Sao Paulo, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Dept Biochem, BR-04039032 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Div Endocrinol, BR-04039032 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Biochem, BR-04039032 Sao Paulo, Brazil
dc.identifier.doi10.1515/JPEM.2008.21.8.811
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000259346200015


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record